What Are Global Osteoporosis Drugs Market 2019-2023?
The global osteoporosis drugs market expected to witness a CAGR of almost 5% during the forecast period. Certain factors that are driving the market growth include new drug approvals and the favorable pipeline, increasing prevalence of osteoporosis, and reimbursement programs and coverage of drug by health insurance.
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the osteoporosis drugs market report
Osteoporosis is considered as a serious public health concern owing to increasing prevalence across the world. Osteoporosis is more common in older women than in older men. The increase in life expectancy rates is due to the improved standard of healthcare facilities and sophisticated treatment options. 200 million women are affected by osteoporosis globally and older people lose their skeletal strength which leads to hip fracture. Hence, the increasing prevalence of osteoporosis is expected to be one of the key factors driving the growth of the osteoporosis drugs market.
The adverse effects of the drugs can be reduced using the transdermal drug delivery system. The system can further increase the bioavailability of drugs to the targeted site and show prolonged action.
Currently, the teriparatide can only be administered as daily subcutaneous injection, as a result, drug compliance is effective. The need for a new route of administration has led to the development of novel teriparatide transdermal microneedle delivery system. The increase in the development of transdermal drug delivery system is expected to be one of the key trends in the osteoporosis drugs market growth.
Comments
Post a Comment